Angiopeptin Inhibits Thymidine Incorporation by Explants of Porcine Coronary Arteries
- 1 February 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 29 (2) , 278-283
- https://doi.org/10.1097/00005344-199702000-00018
Abstract
Angiopeptin, a stable octapeptide analog of somatostatin, inhibits proliferation in a variety of cancer cell lines. We studied the effect of angiopeptin on 3H-thymidine uptake into ring segments from the porcine coronary tree. The incorporation of 3H-thymidine into segments of porcine left anterior descending (LAD) coronary artery was time dependent and reached a plateau after 48 h. The addition of angiopeptin (48.1 and 96.2 nM) to the culture medium significantly inhibited 3H-thymidine incorporation into the segments by 36.7 +/- 10.1% and 48.3 +/- 2.3% of the control, respectively. Forskolin (100 microM), inhibited 3H-thymidine incorporation (52.7 +/- 10.1%) to the same degree as did angiopeptin (96.2 nM). Incubation of the segments with 125I-labeled angiopeptin, for 2 h at 37 degrees C, showed angiopeptin uptake to be time dependent and exhibited a first-order kinetics, reaching equilibrium after 30 min. Autoradiographic studies showed a uniform distribution of angiopeptin within the endothelium, media, and adventitia. Most of the labeling was associated with the nuclei of the cells. Angiopeptin, after 30-min incubation, did not significantly modify the basal levels of cyclic adenosine monophosphate (cAMP). In contrast, forskolin (100 microM) elicited a 50-fold increase of the basal levels of cAMP. These results indicate that in addition to its endocrine effects, angiopeptin reduces the rate of proliferation by acting directly on the vessel wall.Keywords
This publication has 40 references indexed in Scilit:
- Angiopeptin (BIM23014C) Inhibits Vascular Smooth Muscle Cell Migration In Vitro Through a G-Protein-Mediated Pathway and Is Associated with Inhibition of Adenylyl Cyclase and Cyclic AMP AccumulationJournal of Cardiovascular Pharmacology, 1995
- Acute changes in growth hormone-releasing hormone secretion after injection of BIM 23014, a long acting somatostatin analog, in ramsLife Sciences, 1992
- Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cellsBiochemical and Biophysical Research Communications, 1992
- Postangioplasty restenosis rate between segments of the major coronary arteriesThe American Journal of Cardiology, 1992
- Peptide inhibition of neointimal hyperplasia in vein graftsJournal of Vascular Surgery, 1991
- Somatostatin analogue rc‐160 inhibits the growth of transplanted colon cancer in ratsInternational Journal of Cancer, 1991
- Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty — A report from the M-HEART GrouptThe American Journal of Cardiology, 1990
- Two G Protein Oncogenes in Human Endocrine TumorsScience, 1990
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984
- Inhibition of adenosine 3′,5′-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormoneBiochemical and Biophysical Research Communications, 1974